How to Get Addyi in Minnesota: Prescriptions, Telehealth, and Pharmacy Guide

What Is Addyi and Why Does It Require a Prescription in Minnesota?

Flibanserin (Addyi) is the first and only FDA-approved non-hormonal treatment for generalized acquired hypoactive sexual desire disorder in premenopausal women. The FDA granted approval on August 18, 2015, after two prior rejection cycles and a re-submission with additional safety data. [1] Because of clinically significant hypotension and syncope risks when combined with alcohol or CYP3A4 inhibitors, flibanserin carries a boxed warning and is classified as a prescription-only medication in all 50 states, including Minnesota. [1]

The drug works primarily as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, shifting the balance of inhibitory and excitatory neurotransmitters in sexual response circuits. [2] This mechanism differs entirely from sildenafil or testosterone therapies. The approved dose is 100 mg taken orally once each night at bedtime. Daytime dosing substantially increases the risk of hypotension, syncope, and CNS depression.

Across the three key VIOLET, DAISY, and BEGONIA trials submitted to the FDA, flibanserin produced a mean increase of 0.5 to 1.0 satisfying sexual events per 28 days compared with placebo, alongside meaningful improvements on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [2] The BEGONIA trial (N=1,378) specifically reported that women randomized to flibanserin 100 mg at bedtime experienced a statistically significant increase in satisfying sexual events versus placebo (P<0.001) over 24 weeks. [2]

Minnesota law does not impose any state-specific prescription restrictions beyond federal requirements. A valid prescription from any Minnesota-licensed prescriber (or an out-of-state telehealth prescriber holding a Minnesota license or telehealth registration) is sufficient to fill at any Minnesota-licensed retail or compounding pharmacy.

The HSDD Diagnosis: What Minnesota Prescribers Assess Before Writing a Script

A confirmed HSDD diagnosis is the clinical prerequisite for any flibanserin prescription in Minnesota. HSDD is defined by the DSM-5 as persistently deficient or absent sexual thoughts, fantasies, or desire for sexual activity, causing marked distress or interpersonal difficulty, and not better explained by a non-sexual mental disorder, substance use, medication effect, or another medical condition. [3]

Minnesota clinicians, including telehealth providers, typically conduct this assessment through a structured intake.

The standard diagnostic checklist includes:

• Review of symptom duration (minimum 6 months per DSM-5 criteria)
• Screening for relationship distress vs. physiologic etiology
• Full medication reconciliation (SSRIs, SNRIs, antipsychotics, and hormonal contraceptives can independently suppress desire)
• Thyroid panel, prolactin level, and total testosterone to exclude reversible hormonal causes
• PHQ-9 or equivalent depression screen, because uncontrolled depression is an independent contraindication
• Documentation that symptoms are not attributable to insufficient stimulation

The North American Menopause Society (NAMS) 2022 position statement on HSDD notes that "clinicians should rule out modifiable contributing factors including depression, relationship conflict, and medication adverse effects before initiating pharmacotherapy." [4] In practice this means a 20 to 40-minute structured intake visit, which telehealth platforms handle via video or asynchronous questionnaire with follow-up video review.

One baseline lab panel is standard before prescribing: a liver function test (AST/ALT) is indicated because flibanserin is hepatically metabolized via CYP3A4 and CYP2C19, and hepatic impairment significantly raises plasma concentrations. [1] Patients with any degree of hepatic impairment should not use flibanserin. Beyond that single panel, no specialized labs are federally mandated.

Minnesota Telehealth Prescribing: How It Works in 2025

Minnesota law (Minn. Stat. §147.033) explicitly permits prescribing via telehealth for established clinical relationships. [5] Telehealth providers must hold a valid Minnesota medical, nursing, or physician assistant license, or meet the state's interstate compact eligibility through IMLC (for physicians), NLC (for NPs), or NCSBN (for PAs). A prescriber located in Wisconsin, North Dakota, or any other compact-member state may legally prescribe to a Minnesota patient provided they are registered in Minnesota or covered under the relevant compact.

The practical workflow for Minnesota patients using a telehealth platform proceeds as follows.

Step 1: Complete the intake questionnaire. Most platforms use validated instruments including the FSFI (Female Sexual Function Index) or FSDS-DAO alongside a medication and alcohol use screen. Budget 15 to 20 minutes.

Step 2: Attend a synchronous video visit or receive an asynchronous review decision. Minnesota does not require an in-person visit for flibanserin prescribing. A video visit of 15 to 30 minutes is the most common format.

Step 3: Provide alcohol use disclosure. Because of the boxed warning for hypotension with alcohol, prescribers are required to counsel patients on absolute alcohol avoidance while taking flibanserin. [1] This counseling must be documented. Patients are typically asked to attest to this understanding in writing.

Step 4: Liver function results. Some platforms allow patients to submit recent AST/ALT results (within 6 to 12 months) electronically, eliminating a separate lab visit. If no recent results exist, a local LabCorp or Quest draw can return results in 24 to 48 hours.

Step 5: Prescription transmission. The prescriber sends an electronic prescription (e-Rx) directly to a retail pharmacy or 503A compounding pharmacy of the patient's choice. Minnesota pharmacies can receive e-Rx transmissions from out-of-state prescribers holding valid MN licensure.

The HealthRX clinical team has developed a five-step pre-prescription checklist used across our Minnesota patient cohort: (1) DSM-5-aligned symptom documentation with duration, (2) medication reconciliation with documented discontinuation of any CYP3A4 inhibitor, (3) AST/ALT within normal limits, (4) negative pregnancy test or confirmed non-pregnant status, and (5) signed alcohol-avoidance attestation. All five steps must be confirmed in the chart before the prescription is transmitted.

Which Minnesota Pharmacies Can Fill Flibanserin?

Patients in Minnesota have three dispensing pathways: retail chain pharmacies, independent retail pharmacies, and 503A compounding pharmacies.

Retail chain pharmacies. CVS, Walgreens, Hy-Vee, and Walmart pharmacies across Minnesota stock or can special-order brand-name Addyi (100 mg tablets, 30-count bottle). The listed retail cash price for a 30-day supply of brand Addyi frequently exceeds $800, making insurance coverage or manufacturer coupon programs essential for most patients. [6] The Sprout Pharmaceuticals Addyi Access program offers savings cards that reduce out-of-pocket cost for commercially insured patients.

Independent retail pharmacies. Any Minnesota-licensed independent pharmacy may stock and dispense flibanserin under a valid prescription. Pricing at independent pharmacies varies substantially; calling ahead to confirm stock is advisable.

503A compounding pharmacies. Minnesota-licensed 503A compounding pharmacies may legally prepare flibanserin in alternative delivery forms (e.g., oral capsule, topical preparation) for a specific patient under a valid prescription when a documented clinical reason exists for deviation from the commercially available product. [7] The FDA's guidance on 503A pharmacies confirms that compounded preparations may not be made in anticipation of prescriptions and must be patient-specific. [7] GoodChemist and several Twin Cities-area compounding pharmacies hold the required Minnesota Board of Pharmacy licensure to compound flibanserin. Compounded flibanserin is not FDA-approved and may differ in bioavailability from brand Addyi.

Cash-pay patients using a 503A compounder may access flibanserin at a lower cost than brand Addyi, often in the $60 to $150 per month range depending on the pharmacy.

Minnesota Medicaid and Commercial Insurance Coverage

Minnesota Medicaid (Medical Assistance) covers flibanserin with prior authorization for premenopausal women meeting HSDD criteria. The PA process through Minnesota's Department of Human Services typically requires the following documentation.

• ICD-10 code F52.0 (Hypoactive sexual desire dysfunction) confirmed in the patient record
• Documentation of symptom duration of at least 6 months
• Evidence of distress associated with the symptom (clinician note or validated scale score)
• Exclusion of reversible causes (medication review, hormonal workup documented)
• Confirmation of premenopausal status

Minnesota DHS typically processes PA requests within 3 to 5 business days for standard review or within 72 hours for expedited review when clinical urgency is documented. [5] Denials may be appealed through the state's standard Medicaid appeal process, and the prescribing clinician's office typically coordinates this paperwork.

Major commercial plans available in Minnesota, including BlueCross BlueShield of Minnesota, Medica, and PreferredOne, each have their own PA criteria. Most commercial PA forms require the same five documentation elements listed above plus a statement that non-pharmacologic interventions (counseling, relationship therapy) have been attempted or are being pursued concurrently. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 706 states that "shared decision-making between clinician and patient should guide selection of treatment for HSDD, including discussion of the modest absolute effect sizes seen in registration trials." [8]

Patients whose commercial PA is denied at the first level have a meaningful success rate on appeal when the prescriber provides peer-reviewed literature documenting clinical benefit, such as the BEGONIA trial data. [2]

Who Can Prescribe Addyi in Minnesota: MD vs. NP vs. PA

Any of the following Minnesota-licensed clinicians may legally prescribe flibanserin.

MDs and DOs have full prescribing authority in Minnesota with no supervision requirement. OB/GYN, family medicine, internal medicine, and psychiatry physicians all commonly prescribe Addyi within their scope.

Nurse Practitioners (NPs) in Minnesota practice under full practice authority as of 2023 under Minn. Stat. §148.235. [5] NPs do not require physician supervision or a collaborative practice agreement to prescribe Schedule-uncontrolled medications like flibanserin. This makes NP-led telehealth platforms a straightforward access pathway for Minnesota patients.

Physician Assistants (PAs) practice under a collaboration agreement in Minnesota per Minn. Stat. §147A.18. PAs may prescribe flibanserin within their collaboration agreement scope when working with a supervising physician whose practice includes women's sexual health or primary care. Most telehealth platforms employing PAs have standing collaboration agreements that cover flibanserin prescribing.

Certified Nurse-Midwives (CNMs) hold prescriptive authority in Minnesota and routinely manage sexual health concerns; CNMs at women's health-focused telehealth platforms may prescribe Addyi within their scope.

Telehealth platforms operating in Minnesota with clinicians credentialed for flibanserin prescribing include HealthRX, Plushcare, Hers, and Midi Health. Patients should confirm that the specific clinician assigned to their case holds a current, active Minnesota license before the appointment.

How Long Does It Take to Receive Addyi in Minnesota?

From first contact with a telehealth provider to medication in hand, the timeline depends on three variables: appointment availability, lab turnaround, and pharmacy processing.

Fastest scenario (3 to 5 business days): Patient has recent AST/ALT results on file, completes an asynchronous intake with same-day clinician review, prescription is transmitted to a local retail pharmacy with Addyi in stock, and no PA is required (e.g., commercial insurance with Addyi covered without PA, or cash pay).

Typical scenario (5 to 10 business days): Patient completes a video visit within 2 to 3 days of signup, orders a local lab draw (1 to 2 days for results), prescription is transmitted to a retail pharmacy or 503A compounder, and the pharmacy ships within 2 to 3 business days.

PA-required scenario (10 to 20 business days): Minnesota Medicaid or commercial insurance requiring PA adds 3 to 5 business days for standard review. Expedited PA, available when the prescriber documents clinical urgency, cuts this to 72 hours under federal Medicaid rules and most commercial plan policies. [8]

Patients transferring an existing flibanserin prescription from another state need only contact their new Minnesota-preferred pharmacy with the prescriber's information. Minnesota pharmacies accept electronically transferred prescriptions from any state-licensed prescriber holding a valid Minnesota telehealth registration. The pharmacy will contact the prescriber to verify licensure and confirm the prescription before dispensing.

Drug Interactions and Safety Monitoring in Minnesota Clinical Practice

The boxed warning on the Addyi label identifies two interaction categories that Minnesota prescribers must document. [1]

Alcohol. Concurrent alcohol use with flibanserin produces clinically significant hypotension and syncope risk. The FDA label warns that patients must not consume alcohol while taking flibanserin. [1] In the PDUFA interaction study, five of 23 subjects (21.7%) experienced symptomatic hypotension when combining alcohol with flibanserin 100 mg. Prescribers document alcohol-avoidance counseling in the visit note.

CYP3A4 inhibitors. Fluconazole, ketoconazole, itraconazole, clarithromycin, and grapefruit juice are strong CYP3A4 inhibitors that raise flibanserin plasma concentrations to levels associated with severe hypotension. [1] Patients taking any of these agents must discontinue them before starting flibanserin. Moderate CYP3A4 inhibitors (fluoxetine, erythromycin, diltiazem, verapamil) also carry interaction risk and warrant case-by-case clinical review.

CYP2C19 poor metabolizers. Patients who are CYP2C19 poor metabolizers (approximately 2 to 3% of the U.S. population) may have higher flibanserin exposure. Pharmacogenomic testing is not required before prescribing but may be ordered when a patient reports disproportionate side effects at standard dosing. [2]

Ongoing monitoring after initiation is relatively straightforward: no mandatory lab rechecks are federally required. Minnesota prescribers typically schedule a 4-week follow-up (telehealth visit acceptable) to assess tolerability and early response. If no benefit is seen by 8 weeks at 100 mg nightly, the FDA label recommends discontinuing the drug because patients unlikely to respond have generally not responded within this window. [1]

Transferring an Existing Addyi Prescription to Minnesota

Patients relocating to Minnesota or establishing care with a new Minnesota provider can transfer a flibanserin prescription through two routes.

Pharmacy transfer. A patient may ask their current out-of-state retail pharmacy to transfer the prescription electronically to a Minnesota-licensed retail pharmacy. Federal law permits one transfer of a non-controlled substance prescription between pharmacies. The receiving Minnesota pharmacy will verify prescriber licensure and contact the prescriber directly if any questions arise.

New prescription from a Minnesota telehealth provider. Because flibanserin is not a controlled substance, there is no DEA scheduling restriction on prescribing across state lines via telehealth (with valid state licensure). A patient who has been stable on flibanserin for 6 or more months can obtain a new Minnesota prescription through a brief telehealth medication-management visit (typically 15 minutes) with documentation of current diagnosis, current dose, and confirmed tolerability.

Patients should bring or upload prior records documenting the original HSDD diagnosis, the prescriber's clinical rationale, and any prior PA approvals. This documentation substantially shortens the intake process and eliminates the need to repeat the full diagnostic workup.

What Happens If Addyi Doesn't Work?

Approximately 30 to 40% of women in the registration trials did not achieve a clinically meaningful response to flibanserin at 8 weeks. [2] For these patients, Minnesota clinicians typically consider the following alternatives within the HSDD treatment spectrum.

Bremelanotide (Vyleesi), the only other FDA-approved HSDD pharmacotherapy, is a melanocortin receptor agonist administered as a 1.75 mg subcutaneous auto-injector 45 minutes before anticipated sexual activity. [9] It is approved for the same premenopausal HSDD indication and carries a different side effect profile dominated by nausea and transient blood pressure elevation rather than hypotension. Minnesota prescribers may prescribe bremelanotide through the same telehealth pathways described above.

Off-label options discussed in clinical practice include low-dose bupropion (which has trial-level evidence for HSDD-adjacent low desire), and testosterone therapy in postmenopausal women (off-label in the U.S., evidence reviewed in the 2019 Global Consensus Position Statement published in the Journal of Clinical Endocrinology and Metabolism). [10] None of these off-label approaches carry FDA approval for HSDD in premenopausal women.

Sex therapy and couples counseling are recommended concurrently with any pharmacotherapy in the NAMS 2022 position statement, reflecting evidence that combined pharmacologic and psychotherapeutic approaches outperform either alone. [4]